Brief: Verrica Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract Highlighting Potential Abscopal Effect Of VP-315 For The Treatment Of Basal Cell Carcinoma At The Upcoming 2026 Society For Investigative Dermatology Annual Meeting
09/04/2026 23:04
April 9 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O: VERRICA PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF LATE-BREAKING ABSTRACT HIGHLIGHTING POTENTIAL ABSCOPAL EFFECT OF VP-315 FOR THE TREATMENT OF BASAL CELL CARCINOMA AT THE UPCOMING 2026 SOCIETY FOR INVESTIGATIVE DERMATOLOGY ANNUAL MEETING Source text: ID:nGNX6jtyMv Further company coverage: VRCA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data